Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The endocrine and metabolic factors influencing neuroinflammation and recovery following traumatic brain injury

Autor: Feeney, Claire

Background: Traumatic brain injury (TBI) is a major cause of psychological and cognitive disability in young adults in the developed world. The prognosis for these patients is uncertain. Neuroinflammation may be an important underlying mechanism. Gro

Externí odkaz: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.700704

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Autor: Blauvelt, Andrew, Silverberg, Jonathan I., Lynde, Charles W., Bieber, Thomas, Eisman, Samantha, Zdybski, Jacek, Gubelin, Walter, Simpson, Eric L., Valenzuela, Fernando, Criado, Paulo Ricardo, Lebwohl, Mark G., Feeney, Claire, Khan, Tahira, Biswas, Pinaki, DiBonaventura, Marco, Valdez, Hernan, Cameron, Michael C., Rojo, Ricardo

Publikováno v: In Journal of the American Academy of Dermatology January 2022 86(1):104-112

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial

Autor: Ständer, Sonja, Kwatra, Shawn G., Silverberg, Jonathan I., Simpson, Eric L., Thyssen, Jacob P., Yosipovitch, Gil, Zhang, Fan, Cameron, Michael C., Cella, Ricardo Rojo, Valdez, Hernan, DiBonaventura, Marco, Feeney, Claire

Publikováno v: Ständer, S, Kwatra, S G, Silverberg, J I, Simpson, E L, Thyssen, J P, Yosipovitch, G, Zhang, F, Cameron, M C, Cella, R R, Valdez, H, DiBonaventura, M & Feeney, C 2023, ' Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis : Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial ', American Journal of Clinical Dermatology, vol. 24, pp. 97-107 . https://doi.org/10.1007/s40257-022-00738-4

Background: Abrocitinib, an oral Janus kinase 1 inhibitor, provided significant itch relief by week 2 in patients with moderate-to-severe atopic dermatitis (AD) in the phase III JADE COMPARE trial. Objectives: This post-hoc analysis of JADE COMPARE a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbff8fe5570e6ed3bdcc5e9e4cc12de5
https://doi.org/10.1007/s40257-022-00738-4